Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer
The combination of doxorubicin with venetoclax is promising for the treatment of p53-WT and mutated TNBC and this work supports further investigation.
Authors
- Stephen G. Smoots
- Anna Schreiber (ORCID: https://orcid.org/0000-0003-2136-2476)
- Adrian T.A. Dominguez (ORCID: https://orcid.org/0000-0003-3387-7805)
- Jennifer R. Diamond (ORCID: https://orcid.org/0000-0002-0703-2772)
- Stacey M. Bagby (ORCID: https://orcid.org/0009-0005-3355-3861)
- Todd M. Pitts (ORCID: https://orcid.org/0000-0002-8123-9894)
- Evan D. Dus
- Marilyn M. Jackson
- Cameron A. Binns (ORCID: https://orcid.org/0009-0005-0529-5930)
Institutions
- The Medical Center of Aurora (US)
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3389/fonc.2025.1549282
- Citations
- 5
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 5.23